StockMarketWire.com - The US Food and Drug Administration has approved the release of Deltex Medical's paediatric probes for use with its CardioQ-ODM+ monitors.

This dedicated paediatric probe is for use on children who weigh three or more kilograms and are under the age of 16. It is designed to monitor drug and fluid therapies in an intensive care environment, specifically cardiac function, evaluation of the surgical patient, fluid analysis in high blood loss surgery and peri-operative fluid management. The paediatric probe has been sold in Europe for the last ten years and has achieved traction in a number of leading children's hospitals.

In the US there are a higher proportion of specialist paediatric hospitals in comparison to Europe, with a dedicated hospital for children in most of the larger cities.

Chief executive Ewan Phillips said: "FDA approval for our paediatric monitoring systems and single patient probes is excellent news for paediatricians in the USA who have, to date, had no safe or easy system in place to understand and monitor sick children's' haemodynamics in a surgical setting." "There is a clear but unfulfilled clinical need for our products and we are already in discussion with a number of major children's' hospitals wanting to trial the CardioQ-ODM+. We expect to generate first revenues in the second half of the year."


At 9:39am: [LON:DEMG] Deltex Medical Group PLC share price was +0.51p at 6.38p



Story provided by StockMarketWire.com